Cypris Therapeutics, a drug discovery company, secures over $500K in pre-seed funding. The round was led by Ichor Life Sciences, a Syracuse-based contract research organization. In addition to having access to Ichor’s equipment and knowledge of drug discovery and development, Cypris will be incubated at Ichor’s facilities.
The money will be used by the business to grow both its operations and growth initiatives.
Cypris Therapeutics, led by CEO Kyle Parella, uses patented technology to synthesise and repeatedly produce complicated small molecule moieties that were previously unachievable for scientists.
Read also – [Funding News] MI-based Vehya Secures $2.1Million in Seed Funding
The molecules are modelled after naturally occurring ones that have been shown to have medicinal qualities. These natural molecules can be altered by it to enhance their medicinal qualities and lessen undesirable side effects. For patients who do not react to current medications, this advancement in synthetic chemistry may raise the bar for care.
Kyle Parella, PhD, Co-Founder and CEO at Cypris said, “At Cypris Therapeutics, we are driven by a mission to develop life-saving therapies for some of the deadliest and therapeutically challenging diseases, Our technology represents a new frontier in cancer treatment, offering hope to patients who currently have limited options.”
Ichor CEO and Founder Kelsey Moody, PhD, MBA stated, “We see vast potential in Cypris Therapeutics’ technology not only as a promising opportunity to develop next generation oncology treatments, but as a platform for iterating natural products for other age-related indications where traditional medicinal chemistry approaches have been elusive.”
About Cypris Therapeutics
Cypris Therapeutics is still dedicated to realising its goal of providing patients with cutting-edge cancer medicines that significantly improve their quality of life. The company is constantly looking for new alliances and funds to help it achieve its lofty objectives.
